Literature DB >> 25447298

Peripherally administered oxytocin modulates latent inhibition in a manner consistent with antipsychotic drugs.

D Feifel1, P D Shilling2, J Hillman2, M Maisel2, J Winfield2, G Melendez2.   

Abstract

BACKGROUND: Peripherally administered oxytocin (OT) has produced antipsychotic drug (APD)-like effects in animal tests that are predictive of APD efficacy. However, these effects have mainly been demonstrated using animal models of schizophrenia-like deficits in prepulse inhibition (PPI) of the startle reflex. Another schizophrenia-relevant abnormality that is the basis of a predictive animal test for APD efficacy is deficient latent inhibition (LI). LI is the normal suppression of a classically conditioned response when the subject is pre-exposed to the conditioned stimulus (CS) before it is paired with the unconditioned stimulus (UCS). Conditioned taste aversion (CTA), the normal avoidance of ingesting a food or liquid by animals when its taste is associated with an aversive experience, was used to test whether OT facilitates LI consistent with APDs.
METHODS: Brown Norway rats, known to naturally display attenuated LI, were aversively conditioned on two consecutive exposures to flavored drinking water (0.1% saccharin) by pairing it with malaise-inducing lithium chloride injections. Concurrent with conditioning, rats received subcutaneous OT (0.02, 0.1, 0.5mg/kg) or saline. Some rats were pre-exposed to the flavored water prior to its aversive conditioning (pre-exposed) while others were not (non pre-exposed). Two days after aversive conditioning the amount of flavored water consumed during a 20-min session was recorded.
RESULTS: As expected, LI, defined as greater consumption by pre-exposed vs. non pre-exposed rats was only weakly exhibited in Brown Norway rats and OT enhanced LI by reducing CTA in pre-exposed rats in a dose-dependent manner, with the 0.02 mg/kg dose producing the strongest effect.
CONCLUSIONS: The facilitation of LI by OT is consistent with the effects produced by APDs and provides further support for the notion that OT has therapeutic potential for schizophrenia.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal models; Antipsychotic drugs; Latent inhibition; Oxytocin; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25447298      PMCID: PMC4382379          DOI: 10.1016/j.bbr.2014.10.023

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  25 in total

Review 1.  The pharmacology of latent inhibition as an animal model of schizophrenia.

Authors:  P C Moser; J M Hitchcock; S Lister; P M Moran
Journal:  Brain Res Brain Res Rev       Date:  2000-09

Review 2.  Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic.

Authors:  C Sue Carter; Ericka M Boone; Hossein Pournajafi-Nazarloo; Karen L Bales
Journal:  Dev Neurosci       Date:  2009-06-17       Impact factor: 2.984

3.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

4.  Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal.

Authors:  Holger Russig; Carol A Murphy; Joram Feldon
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

5.  The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating.

Authors:  David Feifel; Paul D Shilling; Annabelle M Belcher
Journal:  Eur Neuropsychopharmacol       Date:  2011-10-01       Impact factor: 4.600

6.  Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs.

Authors:  I Weiner; E Shadach; R Barkai; J Feldon
Journal:  Neuropsychopharmacology       Date:  1997-01       Impact factor: 7.853

7.  Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism.

Authors:  Mariaelvina Sala; Daniela Braida; Daniela Lentini; Marta Busnelli; Elisabetta Bulgheroni; Valeria Capurro; Annamaria Finardi; Andrea Donzelli; Linda Pattini; Tiziana Rubino; Daniela Parolaro; Katsuhiko Nishimori; Marco Parenti; Bice Chini
Journal:  Biol Psychiatry       Date:  2011-02-21       Impact factor: 13.382

Review 8.  Latent inhibition in humans: data, theory, and implications for schizophrenia.

Authors:  R E Lubow; J C Gewirtz
Journal:  Psychol Bull       Date:  1995-01       Impact factor: 17.737

9.  Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.

Authors:  N S Gray; L S Pilowsky; J A Gray; R W Kerwin
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

10.  Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.

Authors:  Ashley A Keiser; Katelin S Matazel; Melissa K Esser; David Feifel; Adam J Prus
Journal:  Exp Clin Psychopharmacol       Date:  2014-09-15       Impact factor: 3.157

View more
  3 in total

Review 1.  A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.

Authors:  David Feifel; Paul D Shilling; Kai MacDonald
Journal:  Biol Psychiatry       Date:  2015-08-13       Impact factor: 13.382

2.  Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial.

Authors:  H Kosaka; Y Okamoto; T Munesue; H Yamasue; K Inohara; T Fujioka; T Anme; M Orisaka; M Ishitobi; M Jung; T X Fujisawa; S Tanaka; S Arai; M Asano; D N Saito; N Sadato; A Tomoda; M Omori; M Sato; H Okazawa; H Higashida; Y Wada
Journal:  Transl Psychiatry       Date:  2016-08-23       Impact factor: 6.222

Review 3.  Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.

Authors:  Kah Kheng Goh; Chun-Hsin Chen; Hsien-Yuan Lane
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.